<div>
                                <figure class="article-image__container">
                                    
                                    
                                    
                                    <img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/01/Solid-Biosciences-430x241.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="430" height="241" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/01/Solid-Biosciences-430x241.jpg"/>
                                    
                                    <figcaption>Solid Biosciences is bidding for enhanced delivery in gene therapy as it drives uptake of its proprietary capsid and initiates Phase III enrolment for its lead programme. Image credit: metamorworks via Shutterstock.com.</figcaption>
                                </figure>
                            </div>
                                             
     
<p>Solid Biosciences is positioning itself for a potentially “transformative” year as it builds on its 2025 success and centres its pipeline around novel platforms, aiming to overcome investment headwinds in the gene therapy sector.</p>



<p>Enhanced delivery methods will be key to making gene therapy “really investable again,” said CEO Bo Cumbo at the JP Morgan Healthcare Conference in San Francisco, US, taking place from 12 to 15 January.</p><div>
<div id="div-gpt-ad-6065588-4"></div>
  
</div><div><div>
                   <div><h3>Go deeper with GlobalData</h3><ul><li><div><figure><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></figure></div><div><div>Reports 
                                                                
                                                                    
                                                                    
                                                                
                                                            </div><h4>LOA and PTSR Model - Lanacogene Vosiparvovec in Hemophilia B  (Fact... </h4></div> </li><li><div><figure><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></figure></div><div><div>Reports 
                                                                
                                                                    
                                                                    
                                                                
                                                            </div><h4>NPVM: Alaunos Therapeutics Inc's Gene-Modified Cell Therapy to Targ... </h4></div> </li></ul> <div>
                    <h5>
                                                Go deeper with GlobalData
                                            </h5>
                    <p>
                        The gold standard of business intelligence.
                    </p>
                    <p>
                            Find out more
                            
                                
                            
                        
                    </p>
                </div>
                </div></div><section><figure><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></figure><h4> Discover B2B Marketing That Performs </h4><p>
						Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
					</p><p>
							Find out more </p></section></div>



<p>The clinical-stage genetic medicine company has secured more than 50 agreements, including licences, across industry and academia for use of its proprietary capsid AAV-SLB101, said Cumbo.</p><div id="slot-one"></div><div id="Sgpollsputhere"></div>



<p>Investor activity in the cell and gene therapy space has stalled in recent years, with several companies choosing to leave the space in favour of more lucrative modalities. However, the market now appears to be strengthening again and is expected to reach $63bn by 2031, according to a report by GlobalData.</p>



<p>GlobalData is the parent company of <em>Pharmaceutical Technology.</em></p>



<p>The AAV-SLB101 capsid is designed to bind endocrine receptors on skeletal and cardiac muscle, while reducing liver biodistribution to address associated toxicities. The main downside of AAV vectors used in currently approved therapies is occurrences of liver toxicity.</p><div> 
                         <div>


            <div>

                <img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/>
            </div>


            <div>

                <span class="gdm-company-profile-unit__form-excerpt">GlobalData Strategic Intelligence</span>
 <div id="gdm-form-wrapper">



                    <h1>
                        US Tariffs are shifting - will you react or anticipate?
                    </h1>
                    <p>Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.</p>
                    <span class="gdm-company-profile-unit__text">By GlobalData</span>
                
          </div>
          </div>  
           </div> Learn more about Strategic Intelligence</div>



<p>A culmination of multiple incremental changes differentiates the capsid from previous generations, said Cumbo.</p>



<h2 id="h-solid-s-platform-technology-in-the-clinic">Solid’s platform technology in the clinic</h2>



<p>Solid Biosciences is using AAV-SLB101 in its one-time gene therapy SGT-003, designed to restore partial function of the dystrophin protein in the X-linked recessive condition Duchenne muscular dystrophy (DMD), which primarily affects males.</p><div id="slot-two"></div>



<p>Safety concerns have prompted wider discussions in the DMD gene therapy landscape, as Sarepta’s Elevidys was linked to two fatalities in non-ambulatory patients, leading to a label alteration restricting use to ambulatory patients in 2025.</p>



<p>In the Phase I/II INSPIRE (NCT06138639) trial, 33 patients have now been dosed with SGT-003. The therapy has been generally well tolerated with a steroid-only immunomodulation regimen, which Cumbo says differentiates the company from the rest of the field. He emphasised the importance of demonstrating to regulators that the company has not “snooped” the external control data, noting that Solid is well aligned with the FDA’s expectations.</p>



<p>In parallel, Solid has enrolled its first participant in the Phase III randomised placebo-controlled IMPACT trial (NCT07160634). Cumbo said that the company wants to show the FDA that they are “not cutting corners” and remains hopeful of gaining accelerated approval, with plans to start a rolling biologics licence application (BLA) by the end of the year.</p>



<p>Outside the US, he highlighted that Solid has been awarded the UK’s Innovative Licensing and Access Pathway (ILAP) designation, which aims to accelerate time to market and expedite patient access. He added that the company could launch the UK’s first gene therapy for DMD.</p>



<p>Sign up here to receive daily updates<em> on the latest healthcare industry trends emerging from the JP Morgan Healthcare conference 2026. </em>Sign up here to receive a comprehensive report<em> after the conference</em>.</p>
<div id="slot-three"></div><p></p>



<div>
    
</div>

SLDB

<p>Solid Biosciences is focusing on its proprietary AAV-SLB101 capsid to enhance gene therapy delivery, aiming for a transformative year. The company has secured over 50 agreements for its technology and is initiating Phase III trials for its gene therapy SGT-003, targeting Duchenne muscular dystrophy. CEO Bo Cumbo emphasized the importance of improved delivery methods to attract investment back into the sector. The market for cell and gene therapy is projected to reach $63 billion by 2031, with Solid aiming for accelerated approval and potential UK launch of its therapy.</p>

JPM26: Solid Biosciences banks on its AAV capsid to catalyse gene therapy success